The small molecule BH3 domain mimetic compounds targeting the hydrophobic groove of Bcl-2 has been very successful strategy against cancer using ABT-73731 and it’s orally bioavailable derivative ABT-263 or navitoclax32. Here, BCL2 is linked to cancer.